E-Binder March 2020
Total Page:16
File Type:pdf, Size:1020Kb
Silver State Script Board Meeting MARCH 26, 2020 Table of Contents Agenda 3 Silver State Scripts Board Summary 9 Current Preferred Drug List (PDL) 13 Previous Meeting minutes 41 Proposed New Classes 66 Neurological Agents Anti-Migraine Agents Calcitonin Gene-Related Peptide 67 (CGRP) Receptor Antagonists Established Drug Classes Being Reviewed Due to the Release of New Drugs 82 Dermatological Agents: Topical Antipsoriatic Agents 83 Hormones and Hormone Modifiers: Antidiabetic Agents - Incretin Mimetics 94 Neurological Agents: Anticonvulsants – Benzodiazepines 109 Established Drug Classes Being Reviewed Due to the Release of New 135 Cardiovascular Agents Antihypertensive Agents Angiotensin- 136 Converting Enzyme Inhibitors (ACE Inhibitors) Established Drug Classes 149 Analgesics: Opiate Agonists 150 Monoclonal Antibodies for the treatment of Respiratory Conditions 166 Respiratory Agents: Nasal Antihistamines 188 Toxicology Agents: Agents for the Treatment of Substance Abuse 202 Agenda 3 NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD AGENDA Date of Publication: February 13, 2020 Date and Time of Meeting: March 26, 2020 at 1:00 PM Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP) Place of Meeting: Springs Preserve 333 S. Valley View Blvd. Las Vegas, Nevada 89107 Webinar Registration: https://optum.webex.com/optum/onstage/g.php?MTID=e0d8a0d 589390e6223ab1a391858b2696 OR www.webex.com, select “Join,” enter Meeting Number 640 139 985, your name and email and then select, “Join.” A Password should not be necessary, but if asked, enter “Medicaid1!” OR Audio Only: (763) 957-6300 Event Number: 649 127 642 Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP). Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: (775)-684-3722 or email [email protected] in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made Items may be taken out of order. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. Public comment is limited to five minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson. 4 2 | Page 1:00 PM – Closed Executive Session Pursuant to NRS 422.405(4), as amended by Senate Bill 378 during the 80th Legislative session, the Board intends to hold a closed session for discussions between the DHCFP, OptumRx and the Silver State Scripts Board regarding the methodology and selection of preferred agents on the Nevada Medicaid Preferred Drug List (PDL). Upon Completion of the Closed Executive Session – 5:00 PM – Public Meeting (Open Session) AGENDA 1. Call to Order and Roll Call 2. Public Comment 3. Old Business a. For Possible Action: Review and Approve Meeting Minutes from September 26, 2019. 4. New Business a. Status Update by DHCFP b. Proposed New Classes 1. Neurological Agents: Anti-Migraine Agents: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists – Acute a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL c. Established Drug Classes Being Reviewed Due to the Release of New Drugs 1. Dermatological Agents: Topical Antipsoriatic Agents a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL 5 3 | Page 2. Hormones and Hormone Modifiers: Antidiabetic Agents – Incretin Mimetics a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL 3. Neurological Agents: Anticonvulsants – Benzodiazepines a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL d. Established Drug Classes Being Reviewed Due to the Release of New Generics 1. Cardiovascular Agents: Antihypertensive Agents Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL e. Established Drug Classes 1. Analgesics: Opiate Agonists (Opiate Agonists, Abuse Deterrent Opiate Agonists) a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL 2. Monoclonal Antibodies for the treatment of Respiratory Conditions a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class 6 4 | Page d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL 3. Respiratory Agents: Nasal Antihistamines a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL 4. Toxicology Agents: Agents for the Treatment of Substance Abuse a. Public Comment b. Drug Class Review Presentation – OptumRx c. For Possible Action: Board Discussion and Action 1. Approve Clinical/Therapeutic Equivalency of Agents in Class d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP e. For Possible Action: Board Discussion and Action 1. Approval of drugs for Inclusion on the PDL f. Report by OptumRx on New Drugs to Market, New Generic Drugs to Market and New Line Extensions g. Closing Discussion 1. Public comments on any subject 2. Date and location of the next meeting 3. Adjournment This notice and agenda have been posted at http://dhcfp.nv.gov/ and https://notice.nv.gov/. ______________________________________________________________________________ Notice of this public meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at http://dhcfp.nv.gov. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours. If requested in writing, a copy of the proposal will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701 at least three days prior to the public workshop. All persons that have requested in writing to receive the public meeting agenda have been duly notified by mail or e-mail. 7 5 | Page Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Division of Health Care Financing and Policy, in writing, at 1100 East William Street, Suite 101, Carson City, or call Tanya Benitez at (775) 684-3730, as soon as possible, or e-mail at [email protected] 8 Summary of Silver State Scripts Board 9 Silver State Scripts Board By statute (NRS 422.4025), the State of Nevada requires the DHCFP to develop and maintain a Preferred Drug List (PDL) to be used for the Medicaid program and CHIP, and each public or nonprofit health benefit plan that elects to use the PDL. The Silver State Scripts Board (formerly known as the Pharmacy & Therapeutics or P&T Committee) was established to identify prescription drugs to be included on the PDL. A governing body of a county, school district, municipal corporation, political subdivision, public corporation or other local government agency of the State of Nevada that provides coverage of prescription drugs pursuant to NRS 287.010 or any issuer of a policy health insurance purchased pursuant to NRS 287.010 may use the PDL developed by DHHS as its PDL. The PDL is not a restricted formulary. Drugs not on the PDL are still available to recipients if they meet the Standard Preferred Drug List Exception criteria.